本文選題：黃芪 + 中藥復(fù)方��； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)以黃芪為君藥中藥復(fù)方治療糖尿病腎病的有效性及安全性。方法:根據(jù)Cochrane協(xié)作網(wǎng)系統(tǒng)評(píng)價(jià)方法,計(jì)算機(jī)檢索Pub Med、中國(guó)知網(wǎng)、萬(wàn)方數(shù)據(jù)庫(kù),同時(shí)手工檢索雜志刊登的相關(guān)文獻(xiàn),全面收集2016年12月之前收錄的以黃芪為君藥中藥復(fù)方治療糖尿病腎病的隨機(jī)對(duì)照試驗(yàn)。采取改良的Jadad量表評(píng)價(jià)文獻(xiàn)質(zhì)量,應(yīng)用Rev Man5.3軟件進(jìn)行Meta分析,分析指標(biāo)為二分類(lèi)資料,用比值比(OR)及其95%可信區(qū)間(95%CI)表示;分析指標(biāo)為連續(xù)型資料,用加權(quán)均數(shù)差(MD)及其95%可信區(qū)間(95%CI)表示。結(jié)果:1.共納入15個(gè)改良的Jadad量表評(píng)分3分以上的隨機(jī)對(duì)照試驗(yàn),共計(jì)1156例糖尿病腎病患者。2.有效性方面:(1)以黃芪為君藥中藥復(fù)方在治療糖尿病腎病與對(duì)照組比較合并效應(yīng)量OR=3.51,95%CI=(2.48,4.95),P0.00001。(2)以黃芪為君藥中藥復(fù)方在降低糖尿病腎病患者空腹血糖方面與對(duì)照組比較合并效應(yīng)量MD=-0.61,95%CI=(-0.93,-0.28),P=0.0002。(3)以黃芪為君藥中藥復(fù)方在降低糖尿病腎病患者餐后2小時(shí)血糖方面與對(duì)照組比較合并效應(yīng)量示MD=-0.85,95%CI=(-1.18,-0.51),P0.00001。(4)以黃芪為君藥中藥復(fù)方在降低糖尿病腎病患者尿白蛋白方面與對(duì)照組比較合并效應(yīng)量示MD=-25.38,95%CI=(-32.74,-18.01),P0.00001。(5)以黃芪為君藥中藥復(fù)方在降低糖尿病腎病患者24小時(shí)尿蛋白定量方面與對(duì)照組比較合并效應(yīng)量示MD=-0.37,95%CI=(-0.51,-0.24),P0.00001。3.安全性方面:認(rèn)為以黃芪為君藥中藥復(fù)方治療糖尿病腎病無(wú)嚴(yán)重不良反應(yīng)。結(jié)論:以黃芪為君藥中藥復(fù)方是相對(duì)安全和有效治療糖尿病腎病的藥物。
[Abstract]:Objective: to evaluate the efficacy and safety of Astragalus membranaceus for diabetic nephropathy. Methods: according to the evaluation method of Cochrane cooperative network system, Pub Med, China Zhiwang, Wanfang database were searched by computer, and the related literatures published in the journal were also searched manually. A randomized controlled trial on the treatment of diabetic nephropathy with astragalus membranaceus as monomial compound was collected before December 2016. The improved Jadad scale was used to evaluate the quality of the literature, and the Meta analysis was carried out by Rev Man5.3 software. The analysis index was classified data, expressed by ratio (OR) and 95% confidence interval (95 CI), and the analysis index was continuous data. The weighted mean difference (MD) and its 95% confidence interval (CI) are used. The result is 1: 1. A total of 1156 diabetic nephropathy patients were enrolled in 15 randomized controlled trials with improved Jadad scores above 3. Effectiveness: 1) Astragalus as the monarch medicine Chinese compound in the treatment of diabetic nephropathy compared with the control group in comparison with the combined effect of the dose of ORX 3.51C95 CIHU 2.48-4.95C P0.00001. 2) Astragalus as the monarch herbal compound in reducing fasting blood glucose in patients with diabetic nephropathy, compared with the control group, the combination of Astragalus membranaceus as the monarch medicine in the treatment of diabetic nephropathy patients compared with the control group (Astragalus membranaceus as your medicine compound of traditional Chinese medicine in reducing 2 hours postprandial blood glucose in diabetic nephropathy patients compared with the control group, the combined effect of MD-0.85 ~ 95CIK-1.18C1-0.51P0.00001.44) Astragalus as your medicine compound can reduce urinary albumin in patients with diabetic nephropathy. Compared with the control group, the combined effect of MD-25.38 / 9595 showed that the combined effect of Astragalus membranaceus as a Chinese medicine in reducing the quantity of 24 hour urine protein in diabetic nephropathy patients was higher than that in the control group. The combined effect quantity showed that the combined effect of MD-0.37-95 and CI-0.31- 0.241- 0.241- 0.241- 0.24kg-P0.00001.3in reducing the quantity of urinary protein in patients with diabetic nephropathy was compared with that in the control group (P 0.00001. 5) and compared with that in the control group. Safety: Astragalus membranaceus as the monarch medicine compound treatment of diabetic nephropathy without serious adverse reactions. Conclusion: astragalus is a safe and effective drug for diabetic nephropathy.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 潘艷;曾紀(jì)斌;龔麗;曾志聰;葉仁群;黃寅鑾;許希雪;林嘉妮;;黃芪消渴方治療糖尿病腎病的臨床研究[J];中醫(yī)藥導(dǎo)報(bào);2016年13期

2 郭茜;陳永華;楊娟;王小星;呂麗君;;黃芪泡服聯(lián)合黃葵膠囊治療早期糖尿病腎病的臨床觀察[J];黑龍江醫(yī)學(xué);2016年03期

3 劉雪梅;肖小惠;李惠林;趙恒俠;劉德亮;劉玲;;自擬黃芪益腎湯治療早期糖尿病腎病的療效和安全性分析[J];中醫(yī)臨床研究;2016年08期

4 王岱岱;;自擬參芪地黃湯治療糖尿病腎病氣陰不足證46例臨床觀察[J];浙江中醫(yī)雜志;2015年08期

5 葉國(guó)青;;黃芪消渴湯治療糖尿病腎病臨床觀察[J];新中醫(yī);2015年08期

6 杜曉琳;鄭曙琴;;黃芪在古代消渴病治療中應(yīng)用規(guī)律研究[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2015年06期

7 王曉男;;中藥黃芪治療糖尿病腎病臨床療效觀察[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2015年06期

8 肖峰;胡雅國(guó);吳石楠;壽旗揚(yáng);蔡月琴;王慧銘;王輝;;黃芪皂苷提取物對(duì)糖尿病大鼠腎臟的保護(hù)作用[J];中國(guó)中藥雜志;2015年10期

9 王永正;;黃芪六味地黃湯治療早期糖尿病腎病30例[J];陜西中醫(yī)學(xué)院學(xué)報(bào);2015年03期

10 楊麗霞;姜良恩;王志程;張邦能;程濤;李曉東;孫文;劉銅華;;中草藥黃酮類(lèi)化合物防治糖尿病腎病的實(shí)驗(yàn)研究進(jìn)展[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2015年05期

相關(guān)碩士學(xué)位論文 前2條

1 姚美;益脾芪連湯治療脾腎氣虛型糖尿病腎病的臨床研究[D];黑龍江省中醫(yī)藥科學(xué)院;2013年

2 梁軍麗;黃芪知母參七湯治療糖尿病腎�、笃冢怅巸商撔停┑呐R床療效觀察[D];福建中醫(yī)學(xué)院;2009年

，

本文編號(hào)：1933077